Latest Regulatory News

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Invictus Energy has completed the Petroleum Production Sharing Agreement process for its Cabora Bassa Project, setting the stage for significant gas exploration and development in Zimbabwe.

Strata Minerals Limited has successfully completed the first tranche of its $1.175 million capital raising, issuing over 55 million shares to investors. The company now awaits shareholder approval to complete the remaining funding.

Aurizon has lodged a proposed ten-year Network Access Undertaking with the Queensland Competition Authority, aiming to secure long-term certainty and enhanced operational incentives for the Central Queensland Coal Network.

DeSoto Resources reports promising initial gold assay results from its maiden drilling program at Dadjan and Tolé in Guinea, highlighting the potential for a large gold system within its extensive landholding.

Mayne Pharma reports mixed early FY26 results with strong prescription growth in Women’s Health and improved Dermatology margins, while strategic reviews and litigation loom.

Ballard Mining has completed an 86,000m infill drilling program at its Baldock gold deposit, delivering strong assay results that support upgrading resources and targeting a maiden Ore Reserve by mid-2026.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

Meteoric Resources has obtained the Preliminary Environmental Licence without restriction for its Caldeira Rare Earth Ionic Clay Project in Brazil, clearing a key regulatory hurdle and keeping the project on track for mid-2026 construction.

Stockland has announced an estimated ordinary dividend of AUD 0.09 per security for the six months ending December 2025, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.

Champion Iron Limited has launched a $289 million all-cash tender offer to acquire Norway’s Rana Gruber ASA, aiming to strengthen its position in the high-grade iron ore market and advance decarbonization in steelmaking.